Cargando…

European LeukemiaNet classification intermediate risk-1 cohort is associated with poor outcomes in adults with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation

Detalles Bibliográficos
Autores principales:	Medeiros, B C, Tian, L, Robenson, S, Laport, G G, Johnston, L J, Shizuru, J A, Miklos, D B, Arai, S, Benjamin, J E, Weng, W-K, Negrin, R S, Lowsky, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4042305/ https://www.ncbi.nlm.nih.gov/pubmed/24879117 http://dx.doi.org/10.1038/bcj.2014.35

Ejemplares similares

Allogeneic hematopoietic cell transplant for normal karyotype acute myeloid leukemia: Indirect evidence of selection for adverse molecular profile
por: Percival, Mary-Elizabeth M., et al.
Publicado: (2015)

European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response
por: Begna, K. H., et al.
Publicado: (2022)

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
por: Hochhaus, A., et al.
Publicado: (2020)

Sirolimus and Mycophenolate Mofetil as Graft-versus-Host Disease Prophylaxis in Myeloablative, Matched Related Donor Hematopoietic Cell Transplantation
por: Johnston, L, et al.
Publicado: (2011)

Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using total lymphoid irradiation and anti-thymocyte globulin conditioning
por: Rezvani, Andrew R., et al.
Publicado: (2015)

Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia
por: Lachowiez, Curtis A., et al.
Publicado: (2022)

European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia
por: Cross, Nicholas C. P., et al.
Publicado: (2023)

Validation and refinement of the 2022 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Rausch, Christian, et al.
Publicado: (2023)

European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera
por: Tremblay, Douglas, et al.
Publicado: (2022)

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
por: Steegmann, J L, et al.
Publicado: (2016)

Outcome prediction by the 2022 European LeukemiaNet genetic-risk classification for adults with acute myeloid leukemia: an Alliance study
por: Mrózek, Krzysztof, et al.
Publicado: (2023)

Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia
por: Herold, Tobias, et al.
Publicado: (2020)

Outcome of 129 Pregnancies in Polycythemia Vera Patients: A Report of the European LeukemiaNET
por: Wille, Kai, et al.
Publicado: (2023)

Diagnosis and Treatment of Chronic Myelomonocytic Leukemias in Adults: Recommendations From the European Hematology Association and the European LeukemiaNet
por: Itzykson, Raphael, et al.
Publicado: (2018)

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol
por: Bataller, Alex, et al.
Publicado: (2022)

Effects of Intermittent Fasting on Response to Tyrosine Kinase Inhibitors (TKIs) in Patients With Chronic Myeloid Leukemia: An Outcome of European LeukemiaNet Project
por: Yassin, Mohamed A., et al.
Publicado: (2021)

Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia
por: Bill, Marius, et al.
Publicado: (2020)

Flow cytometric analysis of myelodysplasia: Pre‐analytical and technical issues—Recommendations from the European LeukemiaNet
por: van der Velden, Vincent H. J., et al.
Publicado: (2021)

Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification
por: Hochman, Michael J., et al.
Publicado: (2023)

Clinicopathological Variables and Outcome in Chronic Myeloid Leukemia Associated With BCR-ABL1 Transcript Type and Body Weight: An Outcome of European LeukemiaNet Project
por: Abdulla, Mohammad A. J., et al.
Publicado: (2021)

Comparison of the 2022 and 2017 European LeukemiaNet risk classifications in a real-life cohort of the PETHEMA group
por: Sargas, Claudia, et al.
Publicado: (2023)

Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
por: Tettero, Jesse M., et al.
Publicado: (2021)

Real-World Experience of Cryopreserved Allogeneic Hematopoietic Grafts during the COVID-19 Pandemic: A Single-Center Report
por: Bankova, Andriyana K., et al.
Publicado: (2022)

A three-gene expression-based risk score can refine the European LeukemiaNet AML classification
por: Wilop, Stefan, et al.
Publicado: (2016)

Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia – implications for the European LeukemiaNet risk classification
por: Eckardt, Jan-Niklas, et al.
Publicado: (2023)

Correction Notice: Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
Publicado: (2022)

Novel dynamic outcome indicators and clinical endpoints in myelodysplastic syndrome; the European LeukemiaNet MDS Registry and MDS-RIGHT project perspective
por: de Witte, Theo, et al.
Publicado: (2020)

Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group
por: Porwit, Anna, et al.
Publicado: (2022)

Allogeneic Hematopoietic Cell Transplantation for Older Adults with Acute Myeloid Leukemia
por: Lipof, Jodi J., et al.
Publicado: (2018)

Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study
por: Stauder, Reinhard, et al.
Publicado: (2018)

Allogeneic Hematopoietic Cell Transplantation in the Treatment of Chronic Lymphocytic Leukemia: Why and When?
por: Delioukina, Maria L., et al.
Publicado: (2010)

S138: VALIDATION OF THE REVISED 2022 EUROPEAN LEUKEMIANET (ELN) RISK STRATIFICATION IN ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Bill, Marius, et al.
Publicado: (2023)

The Role of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Leukemia
por: Algeri, Mattia, et al.
Publicado: (2021)

Advances in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia
por: Nannya, Yasuhito, et al.
Publicado: (2022)

Allogeneic hematopoietic cell transplant for hairy cell leukemia: EBMT experience
por: Chihara, Dai, et al.
Publicado: (2022)

Morphologic leukemia-free state in acute myeloid leukemia is sufficient for successful allogeneic hematopoietic stem cell transplant
por: Pabon, Cindy M., et al.
Publicado: (2021)

Cytomorphology review of 100 newly diagnosed lower-risk MDS patients in the European LeukemiaNet MDS (EUMDS) registry reveals a high inter-observer concordance
por: de Swart, Louise, et al.
Publicado: (2017)

Allogeneic hematopoietic stem cell transplantation for acute leukemia with Gilbert's syndrome
por: Yu, Guo-Pan, et al.
Publicado: (2011)

Outcome of allogeneic hematopoietic cell transplantation in patients with adult T‐cell leukemia
por: Kamiunten, Ayako, et al.
Publicado: (2018)

Progress in Allogeneic Hematopoietic Cell Transplantation in Adult T-Cell Leukemia-Lymphoma
por: Utsunomiya, Atae
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fhinf97v2nfa3podl3al75j6tf